RESEARCH ARTICLE
Width of 3. Ventricle: Reference Values and Clinical Relevance in a Cohort of Patients with Relapsing Remitting Multiple Sclerosis
Martin Müller 1, 2, *, Regina Esser1, Katarina Kötter1, Jan Voss1, Achim Müller1, Petra Stellmes1
Article Information
Identifiers and Pagination:
Year: 2013Volume: 7
First Page: 11
Last Page: 16
Publisher ID: TONEUJ-7-11
DOI: 10.2174/1874205X01307010011
Article History:
Received Date: 2/1/2013Revision Received Date: 28/2/2013
Acceptance Date: 12/3/2013
Electronic publication date: 3/5/2013
Collection year: 2013

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Objectives:
To estimate the quantity of multiple sclerosis (MS) patients with brain atrophy as indicated by third ventricular enlargement using transcranial colourcoded ultrasound (TCCS).
Methods:
The width of the 3. ventricle was assessed by TCCS in 70 healthy controls (male 31, female 39, mean age 41 ± 15 years, age range 18 – 79 years), and in a cohort of 54 patients with relapsing remitting MS (male 16, female 38, mean age 40 ± 10 years, median EDSS 2 [1-3]).
Results:
In the controls, the width of the 3. ventricle increased with age (without any sex differences) from 3.0 ± 0.76 mm in the age group < 40 years to 4.0 ± 0.74 mm in the age group of 60 years or more (ANOVA p=0.0001). Derived from regression analysis, the upper limit of the 95% Confidence Interval for each year provided cutoff points according to which 14 of 54 patients (25%) exhibited an enlarged 3. ventricle. In a multivariate regression analysis, the width of the 3. ventricle over all MS patients was significantly related to EDSS (Spearman rho , r=0.446, p<0.005) and to MS duration (r=0.319, p<0.005).
Conclusions:
Even in MS patients in good clinical conditions the rate of patients with brain atrophy determined by TCCS is high.